Telix Pharmaceuticals (NASDAQ:TLX) Receives “Buy” Rating from HC Wainwright

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 156.41% from the company’s previous close.

A number of other brokerages have also recently issued reports on TLX. Royal Bank Of Canada started coverage on shares of Telix Pharmaceuticals in a research note on Monday, December 15th. They issued a “hold” rating for the company. Citigroup started coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 price target for the company. UBS Group cut their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Wall Street Zen cut Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Down 0.1%

Shares of NASDAQ TLX opened at $7.80 on Monday. Telix Pharmaceuticals has a one year low of $7.72 and a one year high of $30.36. The firm’s 50 day simple moving average is $9.79 and its two-hundred day simple moving average is $11.84.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in shares of Telix Pharmaceuticals in the third quarter valued at about $1,883,000. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals in the second quarter worth about $3,037,000. Portland Investment Counsel Inc. purchased a new position in Telix Pharmaceuticals during the 3rd quarter valued at about $1,225,000. Lazard Asset Management LLC purchased a new position in Telix Pharmaceuticals during the 3rd quarter valued at about $1,097,000. Finally, Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.